How Biotechs Are Using Proteomics to Find New Drug Targets

Biotech has spent decades reading the genome. Now a wave of startups is reading the proteome—the full set of proteins expressed by a cell. Lucas and Luna dig into why proteomics is suddenly investable, not just academic. They look at Seer, a startup that went public with a proteomics platform, and how its technology works: engineered nanoparticles that capture the entire protein soup from a blood sample, then mass spectrometry reads it all. They discuss the key problem proteomics solves: many diseases are driven by proteins, not genes, and most drug targets are proteins. The episode also covers the challenge: the proteome is 100x more complex than the genome, and it changes constantly. They touch on why big pharma like Novartis and Roche are signing proteomics deals, and what it means for drug discovery timelines. By the end, listeners understand why this may be the next big platform shift in biotech. #Proteomics #DrugDiscovery #BiotechStartups #Seer #MassSpectrometry #ProteinBiomarkers #Novartis #Roche #PrecisionMedicine #GenomicsVsProteomics #BiotechInvesting #PlatformBiotech #Business #Technology #LifeSciences #FexingoBusiness #BusinessPodcast #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo